RxDoctor Payments Data

Jacqueline Christie

Psychiatric/Mental Health · Hudson, NYNPI 1811591589

Payments from drug & device makers

$3,251in general payments, 2019–2025

Across 154 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$733
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$730
  • Alkermes, Inc.$686
  • Braeburn Inc.$304
  • Otsuka America Pharmaceutical, Inc.$289
  • Vanda Pharmaceuticals Inc.$186
  • plus $323 from 7 others

What the payments were for

  • Food & beverage$3,20298%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,251 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$8,732
Medicare patients
20
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl51$72,978
CaplytaLumateperone Tosylate30$41,985
RexultiBrexpiprazole20$30,317
Lurasidone Hcl13$4,231
Duloxetine Hcl184$3,817
Quetiapine Fumarate109$2,001
Methylphenidate ErMethylphenidate Hcl26$1,868
Bupropion XlBupropion Hcl149$1,742
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$1,520
Clozapine38$1,504
Mirtazapine135$1,430
Perphenazine37$1,209
Olanzapine97$1,152
Buspirone Hcl93$1,077
Venlafaxine Hcl ErVenlafaxine Hcl113$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$733$72,97851 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$730$41,98530 claims
Otsuka America Pharmaceutical, Inc.Rexulti$289$30,31720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Hudson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →